Immuneering Corporation Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Immuneering Corporation is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on oncology with the aim of extending survival for cancer patients. The company pursues a novel therapeutic approach built around a class of medicines it terms Deep Cyclic Inhibitors. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily MEK inhibitor designed to improve durability and tolerability and to broaden indications to MAPK pathway–driven tumors, including pancreatic cancer. The pipeline also includes programs at earlier stages of development in oncology.

Its target population includes patients with MAPK-pathway–driven solid tumors, notably pancreatic cancer. In April 2026, Immuneering presented new survival data at ASCO from an expanded first-line pancreatic cancer cohort treated with atebimetinib in combination with mGnP.

Sign up for free to view info

Company overview Employee directory